RecruitingNot ApplicableNCT06989320

Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease

Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Formers


Sponsor

University of Alabama at Birmingham

Enrollment

80 participants

Start Date

May 27, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial study is to test if patients with idiopathic calcium oxalate kidney stones have an increased production of oxalate by the body, which would lead to increased urinary excretion of oxalate. The study will recruit adult patients with a history of calcium oxalate kidney stones and healthy volunteers without kidney stones. Participants will ingest fixed diets containing low amounts of oxalate for 5 days ingest a soluble form of glycolate and vitamin C collect urine, blood, stool during the dietary and oral dosing portions of the study and also collect breath sample during the oral glycolate test


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria6

  • age 18-80 yrs
  • Body Mass Index \> 18.5 kg/m2
  • Normal fasting serum electrolytes on comprehensive metabolic profile
  • Willing to ingest fixed diets
  • Willing to stop supplements (vitamins including vitamin C, calcium (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, probiotics) for 2 weeks before start and during study.
  • For stone formers: first time or recurrent Calcium Oxalate stone former. Composition of most recent stone ≥ 50% calcium oxalate if available, uric acid component \<20%

Exclusion Criteria9

  • Chronic Kidney Disease stage 4-5
  • Primary hyperoxaluria, Enteric (secondary) hyperoxaluria
  • Liver, bowel, endocrine or renal diseases (other than idiopathic Calcium Oxalate kidney stones) or any other condition that may influence the absorption, transport or urinary excretion of ions, which will compromise the interpretation of results, including: Cystic fibrosis, Celiac disease, Cystinuria, Uric acid stone former, Nephrotic syndrome, Sarcoidosis, Renal tubular acidosis, Primary hyperparathyroidism, Neurogenic bladder, Urinary diversion, Chronic diarrhea, Bariatric surgery, Inflammatory bowel disease
  • Pregnancy or breast-feeding
  • Incompatible dietary requirements with the study, food allergies or intolerance to any of the foods in study menus
  • Active malignancy or treatment for malignancy within 12 months prior to screening
  • Utilization of immunosuppressive medication
  • Uncontrolled hypertension or diabetes
  • Diabetes type 1

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTLow-oxalate diet and glycolate dosing

Low-oxalate diet 4 days of fixed eucaloric diet with low oxalate (\<60 mg/day), normal calcium content (600-1000 mg/day)

DIETARY_SUPPLEMENTOral glycolate dosing

Oral 13C-glycolate dosing (0.5 mg/kg)

DIETARY_SUPPLEMENTOral 13C- ascorbic acid dosing

Oral 13C- ascorbic acid dosing (0.75 mg/kg)


Locations(2)

United States, Alabama University of Alabama at Birmingham

Birmingham, Alabama, United States

University of Texas South Western Medical Center

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06989320


Related Trials